endocannabinoid palmitoylethanolamide (PEA)
PreclinicalSmall molecule
endocannabinoid palmitoylethanolamide (PEA) is one of 2 small molecule programs targeting LCH. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1 competitor in LCH
#DrugCompanyPhaseTrials
1Phosphatidylcholine
SanofiPreclinical
endocannabinoid palmitoylethanolamide (PEA)
UUniversity of Roma La Sapienza
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Roma La Sapienza